Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer
Steven Joniau, Paolo Gontero(Fondazione Ricerca Molinette), Markus Graefen(Eppendorf (Germany)), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Jochen Walz(Institut Paoli-Calmettes), Giorgio Gandaglia(Vita-Salute San Raffaele University), G. Marchioro(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Burkhard Kneitz(Universitätsklinikum Würzburg), Martin Spahn(Universitätsklinikum Würzburg), Francesco Montorsi(Vita-Salute San Raffaele University), R. Jeffrey Karnes(Mayo Clinic), A Tizzani(University of Turin), D. Frohneberg(Städtisches Klinikum Karlsruhe), Paul Van Cangh, Lorenzo Tosco(KU Leuven), Chao‐Yu Hsu(National Chung Hsing University), Pia Bader(Städtisches Klinikum Karlsruhe)
Cited by 38
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
|The Lancet|2005|1.1k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k